Request for Nominations for Voting Members on the Tobacco Products Scientific Advisory Committee, 58503-58504 [2022-20866]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 186 / Tuesday, September 27, 2022 / Notices
jspears on DSK121TN23PROD with NOTICES
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2022–N–0571 for ‘‘Ortho-phthalates for
Food Contact Use; Reopening of the
Comment Period; Request for
Information.’’ Received comments,
those filed in a timely manner (see
ADDRESSES), will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Dockets Management Staff
between 9 a.m. and 4 p.m., Monday
through Friday, 240–402–7500.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ We
will review this copy, including the
claimed confidential information, in our
consideration of comments. The second
copy, which will have the claimed
confidential information redacted/
blacked out, will be available for public
viewing and posted on https://
www.regulations.gov. Submit both
copies to the Dockets Management Staff.
If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
VerDate Sep<11>2014
17:51 Sep 26, 2022
Jkt 256001
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
Dated: September 20, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
FOR FURTHER INFORMATION CONTACT:
SUMMARY:
Jessica Urbelis, Center for Food Safety
and Applied Nutrition (HFS–275), Food
and Drug Administration, 5001 Campus
Dr., College Park, MD 20740, 240–402–
5187; or Meadow Platt, Office of
Regulations and Policy (HFS–024),
Center for Food Safety and Applied
Nutrition, Food and Drug
Administration, 5001 Campus Dr.,
College Park, MD 20740, 240–402–2378.
In the
Federal Register of May 20, 2022 (87 FR
31090), FDA published a notice with a
60-day comment period to request data
and information on the current food
contact uses, use levels, dietary
exposure, and safety data on any orthophthalates currently used in food
contact applications. We originally gave
interested persons until July 19, 2022, to
provide data and information.
Following publication of the notice,
FDA received a request to allow
interested parties additional time to
comment. The request asserted that 60
days was insufficient to respond fully to
FDA’s specific requests for comments
and to allow potential respondents to
thoroughly evaluate and address
pertinent issues and requested that FDA
extend the comment period by an
additional 6 months. We have
considered this request and, because the
request came too late for us to extend
the comment period before it expired,
we are reopening the comment period
for 90 days. FDA believes that this
additional 90 days will allow time for
interested parties to submit data and
other information to support our review
of the current use levels and safe use of
certain ortho-phthalates in food contact
applications.
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
58503
[FR Doc. 2022–20832 Filed 9–26–22; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2018–N–3263]
Request for Nominations for Voting
Members on the Tobacco Products
Scientific Advisory Committee
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is requesting
nominations for voting members to
serve on the Tobacco Products Scientific
Advisory Committee, in the Center for
Tobacco Products. Nominations will be
accepted for upcoming vacancies
effective January 31, 2023, with this
notice. FDA seeks to include the views
of women and men, members of all
racial and ethnic groups, and
individuals with and without
disabilities on its advisory committees
and, therefore, encourages nominations
of appropriately qualified candidates
from these groups.
DATES: Nominations received on or
before November 28, 2022, will be given
first consideration for membership on
the Tobacco Products Scientific
Advisory Committee. Nominations
received after November 28, 2022, will
be considered for nomination to the
committee as later vacancies occur.
ADDRESSES: All nominations for
membership should be sent
electronically by logging into the FDA
Advisory Nomination Portal: https://
www.accessdata.fda.gov/scripts/
FACTRSPortal/FACTRS/index.cfm.
FOR FURTHER INFORMATION CONTACT:
Regarding all nomination questions for
membership, the primary contact is:
Serina Hunter-Thomas, Office of
Science, Center for Tobacco Products,
Food and Drug Administration,
Document Control Center, 10903 New
Hampshire Ave., Bldg. 71, Rm. G335,
Silver Spring, MD 20993–0002, 1–877–
287–1373 (choose Option 5), email:
TPSAC@fda.hhs.gov.
Information about becoming a
member on an FDA advisory committee
can also be obtained by visiting FDA’s
website at: https://www.fda.gov/
AdvisoryCommittees/default.htm.
E:\FR\FM\27SEN1.SGM
27SEN1
58504
Federal Register / Vol. 87, No. 186 / Tuesday, September 27, 2022 / Notices
FDA is
requesting nomination for voting
members on the Tobacco Products
Scientific Advisory Committee.
SUPPLEMENTARY INFORMATION:
I. General Description of the Committee
Duties
The Tobacco Products Scientific
Advisory Committee advises the
Commissioner of Food and Drugs (the
Commissioner) or designee in
discharging responsibilities related to
the regulation of tobacco products. The
Committee reviews and evaluates safety,
dependence, and health issues, among
others, relating to tobacco products and
provides appropriate advice,
information, and recommendations to
the Commissioner.
jspears on DSK121TN23PROD with NOTICES
II. Criteria for Voting Members
The Committee shall consist of 12
members, including the Chair. Members
and the Chair are selected by the
Commissioner or designee from among
individuals knowledgeable in the fields
of medicine, medical ethics, science, or
technology involving the manufacture,
evaluation, or use of tobacco products.
Almost all non-Federal members of this
Committee serve as Special Government
Employees. The Committee shall
include nine technically qualified
voting members, selected by the
Commissioner or designee. The nine
voting members shall be physicians,
dentists, scientists, or healthcare
professionals practicing in the areas of
oncology, pulmonology, cardiology,
toxicology, pharmacology, addiction,
epidemiology, behavioral health, or any
other relevant specialty. One member
shall be an officer or employee of a State
or local government or of the Federal
Government. The final voting member
shall be a representative of the general
public. Members will be invited to serve
for terms of up to 4 years.
III. Nomination Procedures
Any interested person may nominate
one or more qualified individuals for
membership on the advisory committee.
Self-nominations are also accepted.
Nominations must include a current,
complete re´sume´ or curriculum vitae for
each nominee, including current
business address and/or home address,
telephone number, and email address if
available and a signed copy of the
Acknowledgement and Consent form
available at the FDA Advisory
Nomination Portal (see ADDRESSES).
Nominations must also specify the
advisory committee for which the
nominee is recommended. Nominations
must also acknowledge that the
nominee is aware of the nomination
unless self-nominated. FDA will ask
VerDate Sep<11>2014
17:51 Sep 26, 2022
Jkt 256001
potential candidates to provide detailed
information concerning such matters
related to financial holdings,
employment, and research grants and/or
contracts to permit evaluation of
possible sources of conflicts of interest.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14,
relating to advisory committees.
Dated: September 21, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022–20866 Filed 9–26–22; 8:45 am]
BILLING CODE 4164–01–P
This notice is being published less than 15
days prior to the meeting due to the urgent
need to meet timing limitations imposed by
the intramural research review cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.242, Mental Health Research
Grants; 93.281, Scientist Development
Award, Scientist Development Award for
Clinicians, and Research Scientist Award;
93.282, Mental Health National Research
Service Awards for Research Training,
National Institutes of Health, HHS)
Dated: September 21, 2022.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–20840 Filed 9–26–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Board of Scientific
Counselors, National Institute of Mental
Health. The meeting will be closed to
the public as indicated below in
accordance with the provisions set forth
in sections 552b(c)(4) and 552b(c)(6),
Title 5 U.S.C., as amended for the
review, discussion, and evaluation of
individual intramural programs and
projects conducted by the National
Institute of Mental Health, including
consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Board of Scientific
Counselors, National Institute of Mental
Health.
Date: October 12–13, 2022.
Time: October 12, 2022, 12:15 p.m. to 5:00
p.m.
Agenda: To review and evaluate personnel
qualifications and performance, and
competence of individual investigators.
Place: Porter Neuroscience Research
Center, Building 35A, 35 Convent Drive,
Bethesda, MD 20892.
Time: October 13, 2022, 11:00 a.m. to 4:30
p.m.
Agenda: To review and evaluate personnel
qualifications and performance, and
competence of individual investigators.
Place: Porter Neuroscience Research
Center, Building 35A, 35 Convent Drive,
Bethesda, MD 20892.
Contact Person: Jennifer E. Mehren, Ph.D.,
Scientific Advisor, Division of Intramural
Research Programs, National Institute of
Mental Health, NIH, 35A Convent Drive,
Room GE 412, Bethesda, MD 20892–3747,
301–496–3501, mehrenj@mail.nih.gov.
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Board of Scientific
Counselors, National Cancer Institute.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in sections
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
National Cancer Institute, including
consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Board of Scientific
Counselors, National Cancer Institute.
Date: November 7–8, 2022.
Time: 11:00 a.m. to 3:10 p.m.
Agenda: To review and evaluate personnel
qualifications and performance, and
competence of individual investigators.
Place: National Cancer Institute, 9609
Medical Center Drive, Rockville, MD 20850
(Virtual Meeting).
Contact Person: Brian E. Wojcik, Ph.D.,
Senior Review Administrator, Institute
Review Office, Office of the Director,
National Cancer Institute, National Institutes
of Health, 9609 Medical Center Drive, Room
3W414, Rockville, MD 20850, 240–276–5660,
wojcikb@mail.nih.gov.
Information is also available on the
Institute’s/Center’s home page: https://
deainfo.nci.nih.gov/advisory/bsc/index.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
E:\FR\FM\27SEN1.SGM
27SEN1
]]>Agencies
[Federal Register Volume 87, Number 186 (Tuesday, September 27, 2022)]
[Notices]
[Pages 58503-58504]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-20866]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2018-N-3263]
Request for Nominations for Voting Members on the Tobacco
Products Scientific Advisory Committee
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is requesting
nominations for voting members to serve on the Tobacco Products
Scientific Advisory Committee, in the Center for Tobacco Products.
Nominations will be accepted for upcoming vacancies effective January
31, 2023, with this notice. FDA seeks to include the views of women and
men, members of all racial and ethnic groups, and individuals with and
without disabilities on its advisory committees and, therefore,
encourages nominations of appropriately qualified candidates from these
groups.
DATES: Nominations received on or before November 28, 2022, will be
given first consideration for membership on the Tobacco Products
Scientific Advisory Committee. Nominations received after November 28,
2022, will be considered for nomination to the committee as later
vacancies occur.
ADDRESSES: All nominations for membership should be sent electronically
by logging into the FDA Advisory Nomination Portal: https://www.accessdata.fda.gov/scripts/FACTRSPortal/FACTRS/index.cfm.
FOR FURTHER INFORMATION CONTACT: Regarding all nomination questions for
membership, the primary contact is: Serina Hunter-Thomas, Office of
Science, Center for Tobacco Products, Food and Drug Administration,
Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G335,
Silver Spring, MD 20993-0002, 1-877-287-1373 (choose Option 5), email:
[email protected].
Information about becoming a member on an FDA advisory committee
can also be obtained by visiting FDA's website at: https://www.fda.gov/AdvisoryCommittees/default.htm.
[[Page 58504]]
SUPPLEMENTARY INFORMATION: FDA is requesting nomination for voting
members on the Tobacco Products Scientific Advisory Committee.
I. General Description of the Committee Duties
The Tobacco Products Scientific Advisory Committee advises the
Commissioner of Food and Drugs (the Commissioner) or designee in
discharging responsibilities related to the regulation of tobacco
products. The Committee reviews and evaluates safety, dependence, and
health issues, among others, relating to tobacco products and provides
appropriate advice, information, and recommendations to the
Commissioner.
II. Criteria for Voting Members
The Committee shall consist of 12 members, including the Chair.
Members and the Chair are selected by the Commissioner or designee from
among individuals knowledgeable in the fields of medicine, medical
ethics, science, or technology involving the manufacture, evaluation,
or use of tobacco products. Almost all non-Federal members of this
Committee serve as Special Government Employees. The Committee shall
include nine technically qualified voting members, selected by the
Commissioner or designee. The nine voting members shall be physicians,
dentists, scientists, or healthcare professionals practicing in the
areas of oncology, pulmonology, cardiology, toxicology, pharmacology,
addiction, epidemiology, behavioral health, or any other relevant
specialty. One member shall be an officer or employee of a State or
local government or of the Federal Government. The final voting member
shall be a representative of the general public. Members will be
invited to serve for terms of up to 4 years.
III. Nomination Procedures
Any interested person may nominate one or more qualified
individuals for membership on the advisory committee. Self-nominations
are also accepted. Nominations must include a current, complete
r[eacute]sum[eacute] or curriculum vitae for each nominee, including
current business address and/or home address, telephone number, and
email address if available and a signed copy of the Acknowledgement and
Consent form available at the FDA Advisory Nomination Portal (see
ADDRESSES). Nominations must also specify the advisory committee for
which the nominee is recommended. Nominations must also acknowledge
that the nominee is aware of the nomination unless self-nominated. FDA
will ask potential candidates to provide detailed information
concerning such matters related to financial holdings, employment, and
research grants and/or contracts to permit evaluation of possible
sources of conflicts of interest.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.
Dated: September 21, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-20866 Filed 9-26-22; 8:45 am]
BILLING CODE 4164-01-P
